Alert: Rating Upgrade (3/18/24)-Cardiff Oncology Inc (NASDAQ: CRDF).

Stock Rating Upgrade

The Value Trend Rating for Cardiff Oncology Inc (NASDAQ: CRDF) improved recently from D to C reflecting improving fundamentals and high Appreciation Potential. Details supporting this higher rating are included in our next report.

Recent Price Action

Cardiff Oncology Inc (NASDAQ: CRDF) stock enjoyed a large increase of 2.8% on 3/18/24. The stock closed at $5.17. This advance was accompanied by normal trading volume. Relative to the market the stock has been exceptionally strong over the last nine months and has risen 24.9% during the last week.

Current PriceTarget Research Rating

CRDF is expected to continue to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.

Cardiff Oncology has a current Value Trend Rating of C (Low Neutral). This VT Rating improved in recent days from D previously. This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Cardiff Oncology has a very low Appreciation Score of 3 but a very high Power Rating of 87, producing the Low Neutral Value Trend Rating.